Jan. 25, 2023 Price forecast | 2 weeks: -2.85% | 1 month: -2.83% | 3 months: -6.95%


PEAR stock forecast

Our latest prediction for Pear Therapeutics Inc's stock price was made on the Jan. 25, 2023 when the stock price was at 1.15$.

In the short term (2weeks), PEAR's stock price should underperform the market by -2.85%. During that period the price should oscillate between -9.86% and +11.52%.

In the medium term (3months), PEAR's stock price should underperform the market by -6.95%. During that period the price should oscillate between -31.16% and +27.74%.

Create a solid portfolio with PEAR

Add PEAR to your portfolio and optimize it!


About Pear Therapeutics Inc

Pear Therapeutics, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of None$ per share.

The book value per share is 0.56$

Pear Therapeutics Inc website


Three months stock forecastJan. 25, 2023


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - - - - - - - 139M 0.56 - - -